Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable

PI: Frank A. Vicini

Disease

  • Lung Cancer

Contact

Michigan: Maria Pappas (248) 553-0606

Topics

  • Lung cancer

Primary Objective:
The primary objective of the trial is to determine whether concurrent MEDI4736 (durvalumab) with cytoxic chemo/radiation improves overall survival (OS) in addition to a standard therapy (chemotherapy and radiation followed by consolidative MEDI4736 (durvalumab)). Secondary objectives include estimation of progression-free survival, best objective response, incidence of local/distant progression, and toxicity.

Patient Population:
Patients with unresectable Stage 3 Non-small cell lung cancer.